<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13806">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927184</url>
  </required_header>
  <id_info>
    <org_study_id>VK2809-201</org_study_id>
    <nct_id>NCT02927184</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viking Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viking Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy, safety, and tolerability of VK2809 in lowering
      LDL-C and liver fat content in patients with primary hypercholesterolemia and fatty liver
      disease. The primary efficacy endpoint is percent change from baseline LDL-C at the end of
      the treatment period (Week 12). Secondary endpoints include effects on liver fat content and
      other liver and lipid markers, as well as effects on safety and tolerability, and
      pharmacokinetic (PK) measurements.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LDL-C in patients receiving VK2809 compared to placebo</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hyperlipidemia</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VK2809 (5mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5mg VK2809 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VK2809 (10mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg VK2809 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VK2809 (10mg QOD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg VK2809 capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VK2809</intervention_name>
    <arm_group_label>VK2809 (5mg)</arm_group_label>
    <arm_group_label>VK2809 (10mg)</arm_group_label>
    <arm_group_label>VK2809 (10mg QOD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Minimum of 10% liver fat as assessed by MRI - Proton Density Fat Fraction

          2. Fasting serum LDL-C &gt;130 mg/dL at screening, &gt;110 mg/dL on lipid lowering medications

          3. Any one of the following:

               1. Triglycerides ≥150 mg/dL or receiving prescription medication for elevated
                  triglycerides.

               2. Systolic blood pressure &gt;130 mmHg or diastolic blood pressure ≥85 mmHg or
                  receiving prescription medication for hypertension.

               3. Waist circumference &gt;40 inches (men) or &gt;35 inches (women)

          4. Body mass index (BMI) 18.50 - 40.00 kg/m2 inclusive at screening

          5. Provide a personally-signed and dated informed consent document

        Exclusion Criteria:

          1. Females of childbearing potential and males unwilling to use barrier birth control
             method (condom) throughout the study

          2. Resting 12-lead ECG showing QTc &gt;450 msec, any tachyarrhythmia or morphology change,
             or any other clinically significant abnormality

          3. Cardiovascular event requiring hospitalization in the past year

          4. History or presence of thyroid disorder

          5. History of malignancy in past 5 years

          6. LDL-C ≥190 mg/dL or familial hypercholesterolemia

          7. Significant hepatic or renal function test abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Mancini</last_name>
    <role>Study Director</role>
    <affiliation>Viking Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne Mancini</last_name>
    <phone>858-704-4674</phone>
    <email>mmancini@vikingtherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine Kelleher, MD</last_name>
    <phone>858-7044679</phone>
    <email>ckelleher@vikingtherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Firmani</last_name>
      <phone>480-305-5734</phone>
      <email>RachelFirmani@radiantresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Horizon Clinical Research Associates, PLLC.</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85295</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Billingsley</last_name>
      <phone>208-346-8900</phone>
      <email>lisab@eliasresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Abey</last_name>
      <email>aabey@hopeclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>eStudy Site- Chula Vista</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angie Hunt</last_name>
      <phone>619-995-5246</phone>
      <email>ahunt@estudysite.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Downtown LA Research Center, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Cisneros</last_name>
      <phone>213-261-3680</phone>
      <email>ccisneros@dtlaresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan P Frias, MD</last_name>
      <phone>213-413-2500</phone>
      <email>jfrias@Clinical-Studies.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Clinical Research</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Huynh</last_name>
      <phone>818-558-7555</phone>
      <email>vhuynh@providenceclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeid Kayali, MD</last_name>
      <email>tmercado@ieliverfoundation.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Goerlitz</last_name>
      <email>debra.goerlitz@ocresearchcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Frances</last_name>
      <phone>805-200-7436</phone>
      <email>jane.frances.vct@gmai.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracey Balentine</last_name>
      <phone>941-756-8680</phone>
      <email>tbalentine@meridienresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GF Professional Research Corp</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yally Perez</last_name>
      <phone>305-821-1000</phone>
      <email>yperez@gfproresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania Cary</last_name>
      <phone>305-279-3545</phone>
      <email>tcary@miamimedtrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare, LLC.</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orlan Romm</last_name>
      <phone>407-654-2724</phone>
      <email>vandyromm@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCI- MetroMedic Walk-in</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tusmar Patel, MD</last_name>
      <email>patelmd15@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHEAR Center, LLC</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Bernard</last_name>
      <phone>917-584-3332</phone>
      <email>adam@chearcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Research Associcates, LLC.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CaShante Sledge</last_name>
      <email>csledge@wakeresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coastal Bend Clinical Research</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Plemons</last_name>
      <phone>361-288-4668</phone>
      <email>scastillo@3cra.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, INC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Douglas Denham, MD</last_name>
      <phone>210-949-0181</phone>
      <email>drdenhamc@ttexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Leticia Martinez</last_name>
      <phone>210-614-7483</phone>
      <email>mariamartinez@radiantresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Physicians Research Options, LLC.</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennie Walker</last_name>
      <phone>385-695-2300</phone>
      <email>jennie.walker@proslc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Dahl, MD</last_name>
      <email>drcdahl@aspclinic.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>October 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
